AUTHORS
Lei Zhang, MD, Jun Shi2, Danny Hsu, MBBS FRACP FRCPA3, Isaac Goncalves, MD4, Xuliang Shen, MD5, Yanrong Wang6, Wenzhe Qian7, Charlie Zhou, MD, MPH8, Eric Hedrick9, Philip Young-Ill Choi, PhD10
AFFILIATIONS
1 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
2 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
3 Liverpool Hospital and University of New South Wales, New South Wales, Australia
4 Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Parkville, Australia
5 Heping Hospital affiliated to Changzhi Medical College, Changzhi, China
6 Keymed Biosciences Co., Ltd., Chengdu, China
7 Keymed Biosciences Co., Ltd., Chengdu, China
8 Lakefront Biotherapeutics, Mechelen, Belgium
9 Lakefront Biotherapeutics, Mechelen, Belgium
10 Haematology, Canberra Health Services, Garran, Australia
ABSTRACT
Background: AICs are rare, chronic disorders characterized by autoantibody-mediated destruction of blood cells, platelets and/or their precursors. Long-lived plasma cells critically sustain in the production of autoantibodies but are not specifically targeted by current therapies. Gamgertamig (CM336/OM336) is an investigational CD3-detuned T cell engager (TCE) targeting B cell maturation antigen (BCMA) which depletes both autoantibody-secreting plasma cells and memory B cells, potentially allowing for a “reset” of the immune system in patients with AIC.
Methods: NCT07083960 and NCT07175493 are parallel ongoing, open-label, phase 1/2 studies evaluating gamgertamig in adults with relapsed/refractory AICs, including immune thrombocytopenia (ITP) and warm, cold, or mixed autoimmune hemolytic anemia (AIHA; wAIHA/CAD/mAIHA). NCT07083960 is a multinational study which is open in Australia and the United States. NCT07175493 is a single-country study in China. In both studies, gamgertamig is administered as a fractionated dose over a maximum of four subcutaneous injections, over a maximum of 3 weeks; dose and schedules are substantially lower than those used in the treatment of plasma cell malignancies. Data are presented across three dose cohorts (low, mid, and high). All patients were considered evaluable for safety, patients with follow-up >28 days were considered evaluable for response.
Results: At the time of analysis, 33 patients with AICs had received gamgertamig, including 22 patients with ITP and 11 with AIHA (wAIHA=9, CAD=1, mAIHA=1). Median disease duration for the ITP and AIHA cohorts was 8.4 years (range: 1.7-46.5) and 3.7 years (range: 1.5-26.5), respectively.
Circulating B cells were rapidly depleted in all patients in mid and high dose cohorts by Day 29. B cell reconstitution occurred in a dose-dependent manner, at approximately 3 and 4 months after completion of dosing in the mid and high dose cohorts, respectively. Consistent with the mechanism of action, hypogammaglobulinemia (IgG <400mg/dL) was observed in 14/33 (42%) and appeared to be dose-dependent.
Among 20 response-evaluable patients with ITP, median follow-up was 141 days (range: 29-253). 18/20 (90%) achieved response [≥30 × 10^9/L and at least double from baseline; 2/3 (66%), 4/5 (80%) and 12/12 (100%) patients in the low, mid, and high dose cohorts, respectively], with normalization of platelet count (≥150 × 10^9/L) observed in 17/18 (94%) responders. The median time to response from first injection was 11 days (range: 4-85). Of the 18 responders, 15 (83%) had an ongoing response at the most recent follow-up. Responses remained durable in 7/9 (78%) patients who had reconstitution of circulating B cells at the time of this analysis [1/1 (100%), 3/4 (75%) and 3/4 (75%) in low, mid and high dose cohorts, respectively].
Among 9 response-evaluable patients with AIHA (wAIHA=7, CAD=1, mAIHA=1), median follow-up was 85 days (range: 57-198). All response-evaluable patients were in the mid and high dose cohorts and all achieved a response, defined as a ≥2 g/dL increase in hemoglobin from baseline: 6/6 (100%) and 3/3 (100%), respectively. Among responders, the median time to response from first injection was 22 days (range: 4-81). Of the 9 responders, 8 (89%) had an ongoing response at the most recent follow-up. At the time of this analysis, in the two patients who had reconstitution of circulating B cells, response remained in one patient [1/2 (50%) in mid dose].
Grade 1 cytokine release syndrome (CRS) occurred in 6/33 patients (18%); no Grade ≥2 events were reported. No cases of immune effector cell-associated neurotoxicity syndrome (ICANS) or other neurotoxicity were observed. Infection was observed in 10/33 (31%) patients; most infections were Grade 1 or 2.
Conclusion: A single, short course of subcutaneous gamgertamig results in rapid normalization of platelet or hemoglobin levels in patients with refractory AICs. Preliminary data suggests potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for AIC, consistent with an “immune reset”. Gamgertamig was generally well tolerated, with an absence of clinically significant CRS and a manageable infection risk. Safety and efficacy findings were consistent across both studies. These findings support future investigation of gamgertamig in larger clinical trials.
DISCLOSURES
Philip Young-Ill Choi, PhD: Novartis - Honoraria; Janssen - Research Funding; Cullinan Therapeutics - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Swedish Orphan Biovitrum - Consultancy (Includes expert testimony); Menarini - Consultancy (Includes expert testimony); Proxima Bio - Consultancy (Includes expert testimony); Sanofi Genzyme - Consultancy (Includes expert testimony); Hengrui - Consultancy (Includes expert testimony); Canberra Health Services - Current Employment